Vision, Integrity, Expertise
Soligenix, Inc. is a development stage biopharmaceutical company committed to developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as oral mucositis, pediatric Crohn’s disease, acute radiation enteritis, and Graft-versus-Host disease (GVHD), and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications.
Wednesday, May 22, 2013Soligenix Announces Issuance of US Patent for its ThermoVax™ Technology
Tuesday, May 14, 2013Soligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohn’s Disease
Friday, May 03, 2013Soligenix Reports First Quarter 2013 Financial Results and Highlights Recent Accomplishments
Partnering with Us
Soligenix is interested in identifying new partnership and merger opportunities for its existing products as well as new in-licensing candidates in the areas of HSC transplant, supportive cancer care, gastrointestinal and biodefense.